136592-20-6

Basic information

• Product Name: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE
• Synonyms: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE;Ethanone, 2-broMo-1-(6-broMo-3-pyridinyl)-;2-BroMo-1-(6-broMopyridin-3-yl)ethanone hydrobroMide
• CAS NO: 136592-20-6
• Molecular Formula: C₇H₅Br₂NO
• Molecular Weight: 278.93
• Mol File: 136592-20-6.mol

Chemical Properties

• Boiling Point: 353.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.943±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.70±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(136592-20-6)
• EPA Substance Registry System: 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE(136592-20-6)

Safety Data

• Hazardous Substances Data: 136592-20-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is used as a synthetic intermediate for the development of new pharmaceuticals, leveraging its chemical properties to create a range of biologically active compounds. Its presence in the synthesis process can contribute to the discovery of novel drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is employed as a key component in the synthesis of various agrochemicals. Its role in this industry is crucial for the production of compounds that can be used in pest control and crop protection, thereby enhancing agricultural productivity.
Used in Organic Synthesis:
2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is utilized as a building block in organic synthesis, where its bromine and pyridine groups facilitate the formation of more complex chemical structures. This application is essential for the creation of a diverse array of organic compounds with specific properties and uses.
Used in Medicinal Chemistry Research:
2-BROMO-1-(6-BROMOPYRID-3-YL)ETHANONE is used as a research compound in medicinal chemistry, where its unique structure is explored for potential applications in drug discovery. Its presence in chemical libraries can aid researchers in identifying new leads for the development of therapeutic agents.

Upstream product

• 139042-59-4 1-(6-bromopyridin-3-yl)ethanone 

Downstream Products

• 1254170-77-8 2-bromo-5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]pyridine 
• 1207747-07-6 2-bromo-5-(2-pyridin-2-yl-1,3-oxazole-4-yl)pyridine 

Relevant articles and documents

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION

The invention relates to a compound which is an indane according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, M, ?, n, p, and q are as defined herein. The compounds are useful in the treatment of antibacterial infection either as stand alone antibiotics, or in combination with further antibiotics.

Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer's Disease Affected Brain

In this study, we synthesized of a series of 2-phenyl- and 2-pyridyl-imidazo[1,2-a]pyridine derivatives and examine their suitability as novel probes for single-photon emission computed tomography (SPECT)-based imaging of β-amyloid (Aβ). Among the 11 evaluated compounds, 10 showed moderate affinity to Aβ(1-42) aggregates, exhibiting half-maximal inhibitory concentrations (IC50) of 14.7 ± 6.07-87.6 ± 39.8 nM. In vitro autoradiography indicated that 123I-labeled triazole-substituted derivatives displayed highly selective binding to Aβ plaques in the hippocampal region of Alzheimer's disease (AD)-affected brain. Moreover, biodistribution studies performed on normal rats demonstrated that all 123I-labeled probes featured high initial uptake into the brain followed by a rapid washout and were thus well suited for imaging Aβ plaques, with the highest selectivity observed for a 1H-1,2,3-triazole-substituted 2-pyridyl-imidazopyridine derivative, [123I]ABC577. This compound showed good kinetics in rat brain as well as moderate in vivo stability in rats and is thus a promising SPECT imaging probe for AD in clinical settings.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X', Y, Y', A, A',Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir

The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit